This trial is active, not recruiting.

Conditions ischemic stroke, coronary heart disease
Sponsor China Academy of Chinese Medical Sciences
Collaborator Guangdong Provincial Hospital of Traditional Chinese Medicine
Start date April 2012
End date December 2014
Trial size 30000 participants
Trial identifier NCT01612585, RSCMI-Ⅴ


This study was advocated by Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences in October 2011.

It was funded by China major scientific and technological specialized project for 'significant new formulation of new drugs'.

Dengzhanxixin is kind of Chinese Medicine injection used for treating Ischemic Stroke and coronary heart disease in many Chinese hospitals.

The purpose of this study is to determine adverse drug events or adverse drug reaction in large sample size 30,000 patients.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective

Primary Outcomes

Number of participants with adverse events; incidence of Dengzhanxixin's ADRs and identify factors that contributed to the occurrence of the adverse reaction.
time frame: The registry procedure will last 3 years only for patients using Dengzhanxixin

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patients using Dengzhanxixin injection from 2012 to 2014 Exclusion Criteria: - none

Additional Information

Official title A Registry Study on Safety Surveillance of Dengzhanxixin (a Chinese Medicine Injection) Used in China
Principal investigator Yan M Xie, BA
Description It is very common that Chinese Medicine Injection used in hospitals in mainland China. However safety problems rose in recent years. There could be many uncertain factors influence Chinese Medicine Injection in clinical practice. Safety surveillance on Chinese Medicine injection is an important problem that needs to be sorted out through large sample observational study. A registry study for Kudiezi injection safety surveillance with 30000 patients will be conducted from April.2012 to December.2014. Eligibility criteria Patients who will use Dengzhanxixin injection in selected hospitals Data will be collected in three aspects by three different forms as following: Form A (green): demographic information ;Form B (pink): adverse drug events/reaction; Form C (white): extracted information from hospital information system and laboratory information system Form
Trial information was received from ClinicalTrials.gov and was last updated in June 2012.
Information provided to ClinicalTrials.gov by China Academy of Chinese Medical Sciences.